ACE抑制剂市场－全球产业规模、份额、趋势、机会和预测，按类型、药物、剂型、应用、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球血管张力素转换酶抑制剂（ACE抑制剂）市场规模为69.4亿美元，预计2030年将以5.75%的复合年增长率成长至97.1亿美元。血管张力素转换酶抑制剂是一类主要用于放鬆血管、降低血压的药物，进而治疗高血压、心臟衰竭和慢性肾臟病等疾病。推动ACE抑制剂市场成长的主要因素是全球心血管疾病和高血压盛行率的上升以及人口老化的加剧。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球ACE抑制剂市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（含巯基的试剂、含二羧酸盐的试剂、含膦酸盐的试剂）
  • 依药物分类（雷米普利、依那普利、贝那普利、福辛普利、卡托普利、莫昔普利、其他）
  • 依剂型（口服锭剂、口服溶液）
  • 依应用领域（心臟衰竭、慢性肾臟病、高血压、糖尿病、心臟病发作、其他）
  • 按最终用户（医院、线上药局、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美ACE抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲ACE抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区ACE抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲ACE抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲ACE抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球ACE抑制剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Pfizer Inc
• Novartis AG
• Johnson & Johnson
• Merck KGaA
• Sanofi SA
• Bayer AG
• United Therapeutics Corporation
• Teva Pharmaceutical Industry
• Bristol-Myers Squibb
• Takeda Pharmaceuticals Company

第十六章：策略建议

第17章调查会社について・免责事项

The Global ACE Inhibitors Market, valued at USD 6.94 Billion in 2024, is projected to experience a CAGR of 5.75% to reach USD 9.71 Billion by 2030. Angiotensin-converting enzyme (ACE) inhibitors constitute a class of pharmaceutical agents primarily utilized to relax blood vessels and reduce blood pressure, thereby managing conditions such as hypertension, heart failure, and chronic kidney disease. The market for these inhibitors is principally driven by the rising global prevalence of cardiovascular diseases and hypertension, alongside an expanding aging population.

Key Market Drivers

The increasing global burden of cardiovascular diseases represents a fundamental driver for the ACE inhibitors market. The widespread prevalence of conditions such as hypertension and heart failure necessitates effective and accessible therapeutic options. These illnesses not only reduce quality of life but also place substantial strain on healthcare systems worldwide. According to the "Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023" published in JACC, in September 2025, the number of prevalent cases of cardiovascular disease reached 626 million globally in 2023, underscoring the vast and growing patient population requiring management for these conditions. This elevated disease burden directly fuels the demand for ACE inhibitors, which are cornerstone treatments for various cardiovascular ailments, driving sustained market expansion.

Key Market Challenges

The potential for adverse effects associated with angiotensin-converting enzyme (ACE) inhibitors presents a significant impediment to market expansion. These side effects, including persistent cough, hyperkalemia, and rare angioedema, frequently lead to patient non-adherence or complete discontinuation of therapy. Such reactions directly diminish the patient base that continues to utilize ACE inhibitor treatments. According to research published in *Frontiers in Cardiovascular Medicine* in 2023, approximately 23.0% of patients prescribed ACE inhibitors were non-persistent with their treatment. This substantial rate of non-persistence, often influenced by the challenges of managing adverse drug reactions, directly limits the therapeutic lifespan of ACE inhibitors for individual patients.

Key Market Trends

The growing adoption of fixed-dose combination therapies represents a pivotal trend in the Global ACE Inhibitors Market. These single-pill combinations enhance patient adherence by simplifying complex treatment regimens, which is crucial for managing chronic conditions like hypertension and heart failure. Such formulations improve therapeutic outcomes by ensuring consistent medication intake. For instance, according to a study published in *J Clin Hypertens (Greenwich)* in August 2025, patients receiving angiotensin-converting enzyme inhibitor or angiotensin receptor blocker combination therapies exhibited the highest adherence rate at 79.18% in 2022-2023, compared to other antihypertensive drug classes. This improvement in adherence directly contributes to better disease control and sustained demand for ACE inhibitor-inclusive fixed-dose combinations.

Key Market Players

• Pfizer Inc
• Novartis AG
• Johnson & Johnson
• Merck KGaA
• Sanofi S.A
• Bayer AG
• United Therapeutics Corporation
• Teva Pharmaceutical Industry
• Bristol-Myers Squibb
• Takeda Pharmaceuticals Company

Report Scope:

In this report, the Global ACE Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

ACE Inhibitors Market, By Type:

• Sulfhydryl-containing Agents
• Dicarboxylate-containing Agents.
• Phosphonate-containing Agents

ACE Inhibitors Market, By Drug:

• Ramipril
• Enalapril
• Benazepril
• Fosinopril
• Captopril
• Moexipril
• Others

ACE Inhibitors Market, By Dosage Form:

• Oral Tablets
• Oral Solutions

ACE Inhibitors Market, By Application:

• Heart Failure
• Chronic Kidney Disease
• Hypertension
• Diabetes
• Heart Attack
• Others

ACE Inhibitors Market, By End user:

• Hospitals
• Online Drug Stores
• Others

ACE Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global ACE Inhibitors Market.

Available Customizations:

Global ACE Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global ACE Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents., Phosphonate-containing Agents)
  • 5.2.2. By Drug (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others)
  • 5.2.3. By Dosage Form (Oral Tablets, Oral Solutions)
  • 5.2.4. By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Others)
  • 5.2.5. By End user (Hospitals, Online Drug Stores, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America ACE Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug
  • 6.2.3. By Dosage Form
  • 6.2.4. By Application
  • 6.2.5. By End user
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States ACE Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug
      • 6.3.1.2.3. By Dosage Form
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End user
  • 6.3.2. Canada ACE Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug
      • 6.3.2.2.3. By Dosage Form
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End user
  • 6.3.3. Mexico ACE Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug
      • 6.3.3.2.3. By Dosage Form
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End user

7. Europe ACE Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug
  • 7.2.3. By Dosage Form
  • 7.2.4. By Application
  • 7.2.5. By End user
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany ACE Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug
      • 7.3.1.2.3. By Dosage Form
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End user
  • 7.3.2. France ACE Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug
      • 7.3.2.2.3. By Dosage Form
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End user
  • 7.3.3. United Kingdom ACE Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug
      • 7.3.3.2.3. By Dosage Form
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End user
  • 7.3.4. Italy ACE Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug
      • 7.3.4.2.3. By Dosage Form
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End user
  • 7.3.5. Spain ACE Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug
      • 7.3.5.2.3. By Dosage Form
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End user

8. Asia Pacific ACE Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug
  • 8.2.3. By Dosage Form
  • 8.2.4. By Application
  • 8.2.5. By End user
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China ACE Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug
      • 8.3.1.2.3. By Dosage Form
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End user
  • 8.3.2. India ACE Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug
      • 8.3.2.2.3. By Dosage Form
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End user
  • 8.3.3. Japan ACE Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug
      • 8.3.3.2.3. By Dosage Form
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End user
  • 8.3.4. South Korea ACE Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug
      • 8.3.4.2.3. By Dosage Form
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End user
  • 8.3.5. Australia ACE Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug
      • 8.3.5.2.3. By Dosage Form
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End user

9. Middle East & Africa ACE Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug
  • 9.2.3. By Dosage Form
  • 9.2.4. By Application
  • 9.2.5. By End user
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia ACE Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug
      • 9.3.1.2.3. By Dosage Form
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End user
  • 9.3.2. UAE ACE Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug
      • 9.3.2.2.3. By Dosage Form
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End user
  • 9.3.3. South Africa ACE Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug
      • 9.3.3.2.3. By Dosage Form
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End user

10. South America ACE Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug
  • 10.2.3. By Dosage Form
  • 10.2.4. By Application
  • 10.2.5. By End user
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil ACE Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug
      • 10.3.1.2.3. By Dosage Form
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End user
  • 10.3.2. Colombia ACE Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug
      • 10.3.2.2.3. By Dosage Form
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End user
  • 10.3.3. Argentina ACE Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug
      • 10.3.3.2.3. By Dosage Form
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global ACE Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Johnson & Johnson
• 15.4. Merck KGaA
• 15.5. Sanofi S.A
• 15.6. Bayer AG
• 15.7. United Therapeutics Corporation
• 15.8. Teva Pharmaceutical Industry
• 15.9. Bristol-Myers Squibb
• 15.10. Takeda Pharmaceuticals Company

16. Strategic Recommendations

17. About Us & Disclaimer